Abstract:BACKGROUND:Non-small cell lung carcinoma (NSCLC) remains the leading cause of cancer deaths in the United States. More than half of NSCLC patients have clinical presentations with locally advanced or metastatic disease at the time of diagnosis. The large-scale genomic analysis of NSCLC has demonstrated that molecular alterations are substantially different between adenocarcinoma (ADC) and squamous cell carcinoma (SqCC). However, a comprehensive analysis of proteins and glycoproteins in different subtypes of NSCLC using advanced proteomic approaches has not yet been conducted.METHODS:We applied mass spectrometry (MS) technology featuring proteomics and glycoproteomics to analyze six primary lung SqCCs and eleven ADCs, and we compared the expression level of proteins and glycoproteins in tumors using quantitative proteomics. Glycoproteins were analyzed by enrichment using a chemoenzymatic method, solid-phase extraction of glycopeptides, and quantified by iTRAQ-LC-MS/MS. Protein quantitation was further annotated via Ingenuity Pathway Analysis.RESULTS:Over 6000 global proteins and 480 glycoproteins were quantitatively identified in both SqCC and ADC. ADC proteins (8337) consisted of enzymes (22.11%), kinases (5.11%), transcription factors (6.85%), transporters (6.79%), and peptidases (3.30%). SqCC proteins (6967) had a very similar distribution. The identified glycoproteins, in order of relative abundance, included membrane (42%) and extracellular matrix (>33%) glycoproteins. Oncogene-coded proteins (82) increased 1.5-fold among 1047 oncogenes identified in ADC, while 124 proteins from SqCC were up-regulated in tumor tissues among a total of 827 proteins. We identified 680 and 563 tumor suppressor genes from ADC and SqCC, respectively.CONCLUSION:Our systematic analysis of proteins and glycoproteins demonstrates changes of protein and glycoprotein relative abundance in SqCC (TP53, U2AF1, and RXR) and in ADC (SMARCA4, NOTCH1, PTEN, and MST1). Among them, eleven glycoproteins were upregulated in both ADC and SqCC. Two glycoproteins (ELANE and IGFBP3) were only increased in SqCC, and six glycoproteins (ACAN, LAMC2, THBS1, LTBP1, PSAP and COL1A2) were increased in ADC. Ingenuity Pathway Analysis (IPA) showed that several crucial pathways were activated in SqCC and ADC tumor tissues.

Glycoprofiling of Early Non-Small Cell Lung Cancer Using Lectin Microarray Technology

Identification of GlcNAcylated Alpha-1-antichymotrypsin As an Early Biomarker in Human Non-Small-cell Lung Cancer by Quantitative Proteomic Analysis with Two Lectins

Protein Glycopatterns in Bronchoalveolar Lavage Fluid as Novel Potential Biomarkers for Diagnosis of Lung Cancer

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Alterations in Serum Protein Glycopatterns Related to Small Cell Lung Cancer, Adenocarcinoma and Squamous Carcinoma of the Lung.

Comprehensive Serum N‐glycan Profiling Identifies a Biomarker Panel for Early Diagnosis of Non‐small‐cell Lung Cancer

Stage-associated differences in the serum N - and O -glycan profiles of patients with non-small cell lung cancer

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.

Glycomic Signatures of Plasma IgG Improve Preoperative Prediction of the Invasiveness of Small Lung Nodules.

Diagnostic Potential of Serum Glycome Analysis in Lung Cancer: A Glycopattern Study

Screening and Identification of Potential Novel Lipid Biomarkers for Non‐small Cell Lung Cancer Using Ultra‐high Performance Liquid Chromatography Tandem Mass Spectrometry

Glycoproteomic Analysis of Tissues from Patients with Colon Cancer Using Lectin Microarrays and Nanolc-Ms/ms.

Identification of N-glycan moiety of tumor marker by lectin microarray

Integrated plasma and exosome long noncoding RNA profiling is promising for diagnosing non-small cell lung cancer

Non-Small Cell Lung Cancer Detection and Subtyping by UPLC-HRMS-Based Tissue Metabolomics

Plasma SNORD42B and SNORD111 As Potential Biomarkers for Early Diagnosis of Non-Small Cell Lung Cancer

Membrane Protein Glycanprofiling of Hepatocellular Carcinoma Cell with Different Metastastic Potential by Lectin Microarray*

Use of Lectin Microarray to Differentiate Gastric Cancer from Gastric Ulcer.

Identification of Aberrantly Expressed Glycans in Gastric Cancer by Integrated Lectin Microarray and Mass Spectrometric Analyses.

Protein Signatures of Molecular Pathways in Non-Small Cell Lung Carcinoma (NSCLC): Comparison of Glycoproteomics and Global Proteomics